Condition: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · Sponsor: Bayer
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| Banner Desert Medical Center | Mesa, Arizona, United States | Withdrawn |
| California Research Inst. | Los Angeles, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Withdrawn |
| UCLA - Mattel Children's Hospital | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | Withdrawn |
| Stanford Univ Med Ctr. / Lucile Packard Children's Hosp | Palo Alto, California, United States | Recruiting |
| Providence Health System - Southern California | Santa Monica, California, United States | Terminated |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance, California, United States | Withdrawn |
| SCL Health | Grand Junction, Colorado, United States | Withdrawn |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Withdrawn |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04142437